SCHEMBL22852741

SCHEMBL22852741

CCOC(=O)c1cc(C(F)(F)F)ccc1Nc1c(C)cccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 2/20 0.48
▸ METTL3 Q86U44 1/20 0.42
▸ TAS2R14 Q9NYV8 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ CDC25A P30304 1/20 0.40
▸ CDC25B P30305 1/20 0.40
▸ CDC25C P30307 1/20 0.40
▸ MAPT P10636 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ P2RX1 P51575 1/20 0.40
▸ TP53 P04637 1/20 0.39
▸ DHODH Q02127 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30294664 0.85 TAS2R14 (0.55) MRGPRX4TAS2R14DHODH
SCHEMBL30294513 0.81 MRGPRX4 (0.45) MRGPRX4TAS2R14KDM4ECYP1A2CYP2C9
SCHEMBL22853414 0.81 MRGPRX4 (0.45) MRGPRX4TAS2R14KDM4ECYP1A2CYP2C9
SCHEMBL987643 0.76 MRGPRX4 (0.51) MRGPRX4KDM4EMAPTTSHRSMN1; SMN2
SCHEMBL22853381 0.76 CFTR (0.47) MRGPRX4TAS2R14KDM4EHPGDDHODH
SCHEMBL22852772 0.76 KDM4E (0.44) MRGPRX4METTL3TAS2R14KDM4ECYP1A2
SCHEMBL30294611 0.76 KDM4E (0.44) MRGPRX4METTL3TAS2R14KDM4ECYP1A2
SCHEMBL30294858 0.76 CDC25B (0.48) MRGPRX4CYP1A2CYP2C9CYP2C19CDC25B
SCHEMBL22853040 0.76 CDC25B (0.48) MRGPRX4CYP1A2CYP2C9CYP2C19CDC25B
SCHEMBL30294825 0.75 SORT1 (0.51) KDM4EHPGDDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 — — US disclosed
WO-2020261114-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B MRGPRX4 510/4885METTL3 3600/4885TAS2R14 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback